LEE STEVEN HYOSIG
Known title: SVP, Controller & CAOCIK: 0001855708
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Mohawk Industries Sets Q3 Earnings Call Amid Mixed Analyst Views. Mohawk Industries has announced it will host its third-quarter earnings conference call, setting the stage for an update on financial performance. Recent market commentary has highlighted the stock as a value play that requires careful monitoring, while other analyses flag it as a consumer stock carrying specific risks. With the share price currently trading near the midpoint of its 52-week range, investors are likely watching for clarity from the upcoming earnings release.
Transaction History
| BHC | ▼ Sell | Tax Withholding | 3,125 | $15K | 7/14/2026 | View on chart |
| BHC | ▲ Buy | Grant | 45,868 | $0 | 2/25/2026 | View on chart |
| BHC | ▲ Buy | Grant | 27,371 | $0 | 7/14/2025 | View on chart |
| MHK | ▼ Sell | Tax Withholding | 91 | $12K | 3/4/2022 | View on chart |
| MHK | ▲ Buy | Grant | 942 | $0 | 3/4/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
BHC appoints interim CEO and looks to raise FY26 EBITDA guidance
Bausch Health announced that its chairman, Thomas J. Appio, will serve as interim chief executive effective immediately. The company and its parent also said they expect to raise the adjusted EBITDA guidance for fiscal year 2026, not including the recently acquired IPR&D business. A separate notice confirms that the firm will release its third‑quarter 2026 results on October 28. Analysts at Zacks included Bausch Health in a recent coverage roundup, highlighting the stock among other health‑care names.
BHC appoints interim CEO and looks to raise FY26 EBITDA guidance. Bausch Health announced that its chairman, Thomas J. Appio, will serve as interim chief executive effective immediately. The company and its parent also said they expect to raise the adjusted EBITDA guidance for fiscal year 2026, not including the recently acquired IPR&D business. A separate notice confirms that the firm will release its third‑quarter 2026 results on October 28. Analysts at Zacks included Bausch Health in a recent coverage roundup, highlighting the stock among other health‑care names.